| Description | CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis. |
| In vitro | In A10 cells, CGP-53353 (DAPH-7) inhibits glucose-induced cell proliferation when administered at 1 μM for 48-96 hours[1].At a concentration of 1 μM for the initial 0-48 hours, CGP-53353 inhibits the glucose-induced increase and acceleration of DNA synthesis in A10 cells. It also blocks the glucose-induced increase in the percentage of S-phase cells[1]. |
| Target activity | PKCβII:0.41 mM, PKCβI:3.8 mM |
| Synonyms | DAPH-7 |
| molecular weight | 365.33 |
| Molecular formula | C20H13F2N3O2 |
| CAS | 145915-60-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: < 7.31 mg/mL DMSO: 50 mg/mL (136.86 mM), Sonication is recommended. |
| References | 1. Yamamoto M, et al. Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279(3):C587-C595. |